Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.
Department of Epidemiology and Health Promotion and Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea.
Am J Kidney Dis. 2017 Oct;70(4):512-521. doi: 10.1053/j.ajkd.2017.03.018.
Reported associations of estimated glomerular filtration rate (eGFR) with cancer risk are inconsistent, and data for the proteinuria-cancer relationship are sparse. We sought to quantify the associations of cancer incidence with eGFR and with proteinuria in a large population-based cohort.
A prospective cohort study.
SETTING & PARTICIPANTS: 242,583 adults (30-74 years old) without a diagnosis of cancer at baseline in the Korean Heart Study, based on health checkups in 1996 to 2004 with follow-up until 2012.
Creatinine-based eGFR (≥90, 60-89, 45-59, and <45mL/min/1.73m) and dipstick proteinuria (undetectable/trace, 1+, 2+, and ≥3+).
Overall and site-specific cancer incidence based on ICD-10 codes.
15,165 cases of cancer were detected. The relationship between eGFR and incidence of any cancer was J shaped, with the lowest risk at 45 to 59mL/min/1.73m. There was 44% higher risk for any cancer among those with eGFRs<45mL/min/1.73m compared with those with eGFRs≥90mL/min/1.73m (HR, 1.44; 95% CI, 1.11-1.87). High proteinuria was also associated with cancer risk, showing a dose-response relationship (HRs of 1.24 [95% CI, 1.13-1.35], 1.38 [95% CI, 1.17-1.63], and 1.66 [95% CI, 1.30-2.12] for 1+, 2+, and ≥3+ vs undetectable/trace). Examining site-specific cancer, eGFR<45 (vs ≥45) mL/min/1.73m was significantly associated with kidney and ureteral cancer, multiple myeloma, and leukemia, whereas proteinuria ≥ 1+ (vs undetectable/trace) was related to a broader set of cancers (ie, stomach, rectal, liver, lung, ovarian, kidney, bladder, and multiple myeloma). After excluding study participants with follow-up less than 3 years, the associations remained consistent for kidney cancer and myeloma with eGFR and for rectal, liver, lung, and ovarian cancer with proteinuria.
Relatively small number of participants with severely reduced eGFR or 70 years or older.
Kidney measures, particularly proteinuria, were associated with increased incidence of cancer. Future studies are needed to better understand the pathophysiologic mechanisms underlying these associations.
估算肾小球滤过率(eGFR)与癌症风险的相关性报道不一致,且蛋白尿与癌症关系的数据也很有限。我们旨在通过一项大型基于人群的队列研究来量化癌症发病率与 eGFR 和蛋白尿的相关性。
前瞻性队列研究。
韩国心脏研究中 242583 名年龄在 30-74 岁之间、基线时无癌症诊断的成年人,基于 1996 年至 2004 年的健康检查,随访至 2012 年。
基于肌酐的 eGFR(≥90、60-89、45-59 和 <45mL/min/1.73m)和尿蛋白试纸(不可检测/痕量、1+、2+和≥3+)。
基于 ICD-10 编码的总体和特定部位癌症发病率。
共检出 15165 例癌症病例。eGFR 与任何癌症发病率之间呈 J 型关系,在 45 至 59mL/min/1.73m 时风险最低。与 eGFR≥90mL/min/1.73m 者相比,eGFR<45mL/min/1.73m 者发生任何癌症的风险高 44%(HR,1.44;95%CI,1.11-1.87)。蛋白尿较高也与癌症风险相关,呈剂量反应关系(HR 分别为 1.24[95%CI,1.13-1.35]、1.38[95%CI,1.17-1.63]和 1.66[95%CI,1.30-2.12],1+、2+和≥3+ vs 不可检测/痕量)。在考察特定部位的癌症时,与 eGFR≥45(vs<45)mL/min/1.73m 相比,eGFR<45mL/min/1.73m 与肾脏和输尿管癌、多发性骨髓瘤和白血病显著相关,而蛋白尿≥1+(vs 不可检测/痕量)与更广泛的一系列癌症相关(即胃、直肠、肝、肺、卵巢、肾、膀胱和多发性骨髓瘤)。排除随访时间不足 3 年的研究参与者后,eGFR 与肾脏癌和骨髓瘤、蛋白尿与直肠癌、肝癌、肺癌和卵巢癌之间的相关性仍然一致。
eGFR 严重降低或年龄≥70 岁的参与者人数相对较少。
肾脏指标,特别是蛋白尿,与癌症发病率增加有关。需要进一步的研究来更好地理解这些相关性的病理生理机制。